Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade

Psychopharmacology

Volumn 196, Issue 1, 2008, Pages 143-155

  Walsh, S L ^a   Chausmer, A E ^b   Strain, E C ^c   Bigelow, G E ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Agonist; Antagonist; Drug abuse; Human; Opiate; Opioid; Opioid receptor

Indexed keywords

BUTORPHANOL; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALTREXONE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURESIS; DRUG EFFECT; FEMALE; HUMAN; MALE; MIOSIS; MOOD; OPIATE ADDICTION; PRIORITY JOURNAL; RESPIRATION DEPRESSION; URINE OSMOLALITY; URINE VOLUME; VITAL SIGN;

ADULT; AFFECT; AROUSAL; BUTORPHANOL; DIURESIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEROIN DEPENDENCE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; PERCEPTION; PREMEDICATION; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 38149040085     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0948-z     Document Type: Article

References (47)

1. Abramson HA, Jarkvik ME, Kaufman MR, Kornetsky C, Levine A, Wagner M (1955) Lysergic acid diethylamide (LSD-25) I. Physiological and perceptual responses. J Psychol 30:3-60
2. Ananthan S, Kezar HS, Carter RL, Saini SK, Rice KC, Wells JL, Davis P, Xu H, Dersch CM, Bilsky EJ, Porreca F, Rothman RB (1999) Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyridomorphinans. J Med Chem 42:3527-3538
3. Butelman ER, Winger G, Zernig G, Woods JH (1995) Butorphanol: Characterization of agonist and antagonist effects in rhesus monkeys. J Pharmacol Exp Ther 272:845-853
4. Commiskey S, Fan L-W, Ho IK, Rockhold RW (2005) Butorphanol: Effects of a prototypical agonist-antagonist analgesic on k-opioid receptors. J Pharm Sci 98:109-116
5. Craft RM, McNiel DM (2003) Agonist/antagonist properties of nalbuphine, butorphanol and (-)- pentazocine in male vs female rats. Pharmacol Biochem Behav 75:235-245
6. Craft RM, Ulibarri CM, Raub DJ (2000) Kappa opioid-induced diuresis in female vs male rats. Pharmacol Biochem Behav 65:53-59
7. Dershwitz M, Rosow CE, DiBiase CE, Zaslavsky A (1991) Comparison of the sedative effects of butorphanol and midazolam. Anesthesiolog 74:717-724
8. Emmerson PJ, Clark MJ, Mansour A, Akil H, Woods JH, Medzihradshky F (1996) Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. J Pharmacol Exp Ther 278:1121-1127
9. First MB, Spitzer RL, Gibbon M (1996) Structured clinical interview for DSM-IV Axis I disorders. New York State Psychiatric Institute, New York State Psychiatric Institute
10. Fraser HF, Van Horn GG, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (A) Attitude of opiate addicts toward opiate-like drugs, (B) A short-term "direct" addiction test. J Pharmacol Exp Ther 133:371-378
11. Gharagozlou P, Demirci H, Clark JD, Lameh J (2002) Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors. BMC Neurosci 3(1):19
12. Gillis JC, Benfield P, Goa KL (1995) Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Drugs 50:157-175
13. Greenwald MK, Stitzer ML (1998) Butorphanol agonist effects and acute physical dependence in opioid abusers: Comparison with morphine. Drug Alcohol Depend 53:17-30
14. Gutrecht JA (1994) Sympathetic skin response. J Clin Neurophysiol 1:519-524
15. Heel RC, Brogden RN, Speight TM, Avery GS (1978) Butorphanol: A review of its pharmacological properties and therapeutic efficacy. Drugs 16:473-505
16. Horan PJ, Ho IK (1989) Comparative pharmacological and biochemical studies between butorphanol and morphine. Pharmacol Biochem Behav 34:847-854
17. Houde RW, Wallenstein SL, Rogers A, Kaiko RF (1976) Annual report of the analgesic studies section of the Memorial Sloan-Kettering Cancer Center, pp 149-168
18. Hunter JC, Leighton GE, Meecham KG, Boyle SJ, Horwell DC, Rees DC, Hughes J (1990) CI-977, a novel and selective agonist for the kappa-opioid receptor. Br J Pharmacol 101:183-189
19. Isbell H, Bellevile RE, Fraser HF, Wikler A, Logan CR (1956) Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication. Arch Gen Psychiatry 76:468-478
20. Jasinski DR, Griffith JD, Pevnick JS, Clark SC (1975) Progress report on studies from the Clinical Pharmacology Section of the Addiction Research Center. Proceedings of the Thirty-Seventh Annual Scientific Meeting Committee on Problems of Drug Dependence. Washington, D.C., pp 136-161
21. Jasinski DR, Griffith JD, Pevnick J, Gorodetzky C, Cone E, Kay D (1977) Progress report from the clinical pharmacology section of the NIDA Addiction Research Center, 37th Annual Meeting, The Committee on Problems of Drug Dependence. National Research Council, National Academy of Sciences, Washington, D.C., pp 133-168
22. Ko M-C, Butelman ER, Traynor JR, Woods JH (1998) Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys. J Pharmacol Exp Ther 285:518-526
23. Kumor KM, Haertzen CA, Johnson RE, Kocher TR, Jasinski DR (1986) Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther 238:960-968
24. Leander JD (1983a) Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at the k-opioid receptor. Eur J Pharmacol 86:467-470
25. Leander JD (1983b) Evidence that nalorphine, butorphanol, and oxilorphan are partial agonists at the k-opioid receptor. Eur J Pharmacol 86:467-470
26. Leander JD, Zerbe RL, Hart JC (1985) Diuresis and suppression of vasopressin by kappa opioids: comparison with mu and delta opioids and clonidine. J Pharmacol Exp Ther 234:463-469
27. Lee MC, Wagner HN, Tanada S, Frost JJ, Bice AN, Dannals RF (1988) Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 29:1207-1211
28. Loder E (2006) Post-marketing experience with an opioid nasal spray for migraine: lessons for the future. Cephalalgia 26:89-97
29. Martin WR (1984) Pharmacology of opioids. Pharmacol Rev 35:283-323
30. Martin WR, Sloan BS, Sapira JD, Jasinski DR (1971) Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 12:245-258
31. Pachter IJ, Evens RP (1985) Butorphanol. Drug Alcohol Depend 14:315-338
32. Peters GR, Ward NJ, Antal EG, Lai PY, deMaar EW (1987) Diuretic actions in man of a selective kappa opioid agonist: U-62,066E. J Pharmacol Exp Ther 240:128-131
33. Pircio AW, Gylys JA, Cavanagh RL, Buyniski JP, Bierwagen ME (1976) The pharmacology of butorphanol, a 3, 14-dihydroxymorphinan narcotic antagonist analgesic. Arch Int Pharmacodyn Ther 220:231-257
34. Preston KL, Bigelow GE (1993) Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther 264:813-823
35. Preston KL, Bigelow GE (2000) Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. J Pharmacol Exp Ther 295:114-124
36. Preston KL, Bigelow GE, Bickel WK, Liebson IA (1989) Drug discrimination in human postaddicts: Agonist-antagonist opioids. J Pharmacol Exp Ther 250:184-196
37. Preston KL, Bigelow GE, Liebson IA (1990) Discrimination of butorphanol and nalbuphine in opioid-dependent humans. Pharmacol Biochem Behav 37: 511-522
38. Preston KL, Liebson IA, Bigelow GE (1992) Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination. J Pharmacol Exp Ther 261
39. Rimoy GH, Bhaskar NK, Wright DM, Rubin PC (1991) Mechanism of diuretic action of spiradoline (U-62066E)-a kappa opioid receptor agonist in the human. Br J Clin Pharmacol 32:611-615
40. Slizgi GR, Ludens JH (1982) Studies on the nature and mechanism of the diuretic activity of the opioid analgesic ethylketocyclazocine. J Pharmacol Exp Ther 220:585-591
41. Vivian JA, Deyoung MB, Sumpter TL, Traynor JR, Lewis JW, Woods JH (1999) k-Opioid receptor effects of butorphanol in rhesus monkeys. J Pharmacol Exp Ther 290:259-265
42. Vonvoigtlander PF, Lahti RA, Ludens JH (1983) U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther 224:7-12
43. Walsh SL, Sullivan JT, Preston KL, Garner JE, Bigelow GE (1996) Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J Pharmacol Exp Ther 279:524-538
44. Walsh SL, Geter-Douglas B, Strain EC, Bigelow GE (2001a) Evaluation of enadoline and butorphanol effects on cocaine self-administration and cocaine pharmacodynamics in humans. Drug Alcohol Depend 60:S231
45. Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001b) Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 157:151-162
46. Zacny JP, Lichtor JL, Thapar P, Coalson DW, Flemming D, Thompson WK (1994) Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers. J Pharmacol Exp Ther 270:579-588
47. Zhu J, Luo L-Y, Li J-G, Chen C, Liu-Chen L-Y (1997) Activation of the cloned human kappa opioid receptor by agonists enhances [35]GTPgammaS binding to membranes: Determination of potencies and efficacies of ligands. J Pharmacol Exp Ther 282:676-684